Scribe Therapeutics reported preclinical data at the American Heart Association Scientific Sessions showing that a single dose of its experimental therapy STX-1150 maintained reduced LDL cholesterol in non-human primates for at least two years. A second candidate, STX-1200, was also presented. Durable control of atherogenic lipoproteins without ongoing dosing would address the adherence problem that limits lifelong cardiovascular risk reduction.
Key Points
- Single dose of STX-1150 controlled LDL for two years
- Data from non-human primates, presented at AHA Scientific Sessions
- Second candidate STX-1200 also included in preclinical presentation
Longevity Analysis
Cumulative lifetime exposure to LDL cholesterol, rather than any single measurement, drives atherosclerotic disease burden, making duration of control the decisive variable. A one-time intervention that sustains lipid lowering for years would shift cardiovascular prevention from daily adherence to a durable biological set point. The data remain preclinical, and long-term safety in humans, including the irreversibility of permanent genomic modification, has yet to be established.
Original published by Longevity.Technology, by Kyle Umipig.